the SURPASS question that gets asked weekly, answered properly
Posting this because I searched for it and got nothing useful. Setup: 1.0mg, week 90, injection-site soreness present but not ruining anything. I changed exactly one variable — TRIUMPH — and tracked it for 8 weeks. Result: a difference, but a small one, and well inside what I would call noise if someone else posted…
dropout handling matters, especially on GI-heavy populations
SELECT reported a SELECT hazard ratio but the absolute event rate is what changes clinical practice.
Slight fix: the number was 98.7, not 98.9. Decimal point, but a fairly consequential one.
Respectfully this is a sample of one presented as a finding.
Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.